Hi Tony, The answers from management re: your post 25 February, highlight Phylogica's competitive edge in targeting CD40L. Efficacy doesn't appear to have been an issue in previous antibody trials. Rather an unfortunate side effect - thromboembolic complications - appears to have torpedoed trials.
Thromboembolism could otherwise be described as an infarct or blockage of blood vessels. Complications could presumably include sudden death.
The lead phylomer peptides avoid the clotting effects which dogged the antibody agents. Additionally, phylomers can be delivered intranasal. As they say, phylomer peptides could be a game changer in targeting CD40L.
Your story on Takeda and its purchase of the rights to Lupus drugs is rather interesting. Lupus is one of the autoimmune diseases which was previously targeted by the anti-CD40L antibodies. Amazing coincidence!
PYC Price at posting:
2.6¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)